DE69638120D1 - Konditionell replizierende virale Vektoren und ihre Verwendung - Google Patents

Konditionell replizierende virale Vektoren und ihre Verwendung

Info

Publication number
DE69638120D1
DE69638120D1 DE69638120T DE69638120T DE69638120D1 DE 69638120 D1 DE69638120 D1 DE 69638120D1 DE 69638120 T DE69638120 T DE 69638120T DE 69638120 T DE69638120 T DE 69638120T DE 69638120 D1 DE69638120 D1 DE 69638120D1
Authority
DE
Germany
Prior art keywords
image
viral
conditionally replicating
vector
replicating viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69638120T
Other languages
English (en)
Inventor
Boro Dropulic
Paula M S Pitha-Rowe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
School of Medicine of Johns Hopkins University
Original Assignee
Johns Hopkins University
School of Medicine of Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, School of Medicine of Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of DE69638120D1 publication Critical patent/DE69638120D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69638120T 1995-11-28 1996-11-27 Konditionell replizierende virale Vektoren und ihre Verwendung Expired - Lifetime DE69638120D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56345995A 1995-11-28 1995-11-28

Publications (1)

Publication Number Publication Date
DE69638120D1 true DE69638120D1 (de) 2010-03-11

Family

ID=24250568

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69638120T Expired - Lifetime DE69638120D1 (de) 1995-11-28 1996-11-27 Konditionell replizierende virale Vektoren und ihre Verwendung
DE69626681T Expired - Lifetime DE69626681T2 (de) 1995-11-28 1996-11-27 Konditionell-replizierende virale vektoren und ihre verwendung.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69626681T Expired - Lifetime DE69626681T2 (de) 1995-11-28 1996-11-27 Konditionell-replizierende virale vektoren und ihre verwendung.

Country Status (19)

Country Link
EP (2) EP1380650B1 (de)
JP (2) JP2000503527A (de)
KR (1) KR100537458B1 (de)
CN (3) CN1651577A (de)
AT (2) ATE234362T1 (de)
AU (3) AU1124997A (de)
BR (1) BR9612574A (de)
CA (1) CA2236868C (de)
CZ (1) CZ294170B6 (de)
DE (2) DE69638120D1 (de)
DK (1) DK0871757T3 (de)
ES (1) ES2188802T3 (de)
HK (1) HK1060152A1 (de)
IL (2) IL124636A0 (de)
NO (1) NO329619B1 (de)
NZ (1) NZ324157A (de)
PT (1) PT871757E (de)
RU (1) RU2270250C2 (de)
WO (1) WO1997020060A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002508338A (ja) * 1997-12-12 2002-03-19 ナルディニ，ルイジ レンチウィルスベクターの治療使用
GB9803351D0 (en) * 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
GB9906177D0 (en) 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
RU2301260C2 (ru) * 2000-09-22 2007-06-20 Вирэкссис Корпорейшн Вирусные векторы с зависимой от условий репликацией и их применение
US20030026791A1 (en) * 2001-03-27 2003-02-06 Laurent Humeau Conditionally replicating vectors for inhibiting viral infections
EP2222861B1 (de) 2007-12-11 2017-12-06 The University of North Carolina At Chapel Hill Polypurintrakt-modifizierte retrovirusvektoren
WO2012051211A2 (en) * 2010-10-11 2012-04-19 Novartis Ag Antigen delivery platforms
CA2977687C (en) * 2015-02-24 2024-02-13 Hwai Wen Chang Conditionally active proteins
CN104711294A (zh) * 2015-04-02 2015-06-17 扬州大学 一种基于禽网状内皮组织增生症病毒ltr的真核表达线性化载体的构建方法及应用
GB2543730A (en) * 2015-05-26 2017-05-03 Andrzejewski Slawomir Use of replication competent vector to eradicate viral latency presented on human immunodeficiency virus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225337A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
IL108719A0 (en) * 1993-02-25 1994-08-26 Ortho Pharma Corp Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them
CA2163129A1 (en) * 1993-05-17 1994-11-24 Flossie Wong-Staal Ribozyme gene therapy for hiv infection and aids
ATE320487T1 (de) * 1994-01-05 2006-04-15 Gene Shears Pty Ltd Ribozyme gegen eine hiv tat sequenz
AU2419595A (en) * 1994-05-10 1995-11-29 Hisamitsu Pharmaceutical Co., Inc. Recombinant human immunodeficiency virus vector and process for producing the same
TW438601B (en) * 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof

Also Published As

Publication number Publication date
KR100537458B1 (ko) 2008-09-08
KR19990071728A (ko) 1999-09-27
RU2270250C2 (ru) 2006-02-20
EP1380650A1 (de) 2004-01-14
CA2236868C (en) 2014-01-21
CA2236868A1 (en) 1997-06-05
CN1207775A (zh) 1999-02-10
CN100390291C (zh) 2008-05-28
IL124636A (en) 2009-12-24
AU1000001A (en) 2001-05-17
ATE455858T1 (de) 2010-02-15
DE69626681D1 (de) 2003-04-17
CZ162498A3 (cs) 1998-12-16
AU767620B2 (en) 2003-11-20
NO329619B1 (no) 2010-11-22
EP0871757A1 (de) 1998-10-21
IL124636A0 (en) 1998-12-06
CN1940076A (zh) 2007-04-04
AU1124997A (en) 1998-06-19
NO982418L (no) 1998-07-27
AU2004200663B2 (en) 2007-07-05
JP4384146B2 (ja) 2009-12-16
ES2188802T3 (es) 2003-07-01
BR9612574A (pt) 2000-04-25
WO1997020060A1 (en) 1997-06-05
DK0871757T3 (da) 2003-07-14
NZ324157A (en) 2000-10-27
JP2000503527A (ja) 2000-03-28
JP2007014341A (ja) 2007-01-25
AU2004200663A1 (en) 2004-04-08
EP0871757B1 (de) 2003-03-12
ATE234362T1 (de) 2003-03-15
CZ294170B6 (cs) 2004-10-13
HK1060152A1 (en) 2004-07-30
NO982418D0 (no) 1998-05-27
EP1380650B1 (de) 2010-01-20
PT871757E (pt) 2003-08-29
DE69626681T2 (de) 2004-02-12
CN1651577A (zh) 2005-08-10

Similar Documents

Publication Publication Date Title
RU95108217A (ru) Дефектный рекомбинантный аденовирус, линия клеток, фармацевтическая композиция
PT836648E (pt) Virus mva recombinante e sua utilizacao
HUP9702377A2 (hu) Önfelerősítő, gyógyszeres úton szabályozható expressziós rendszerek
CY1115405T1 (el) Αλληλουχιες κυκλοϊου που συνδyαζονται με την ασθενεια της καχεξιας του χοιριδιου (map)
DE69519521D1 (de) Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
IL207348A0 (en) Circular dna molecules, processes for their preparation, pharmaceutical compositions comprising them, and use thereof in the manufacture of medicinal products for producing recombinant proteins in vivo
HUP0003911A2 (hu) Neoplazmák kezelése vírusokkal
DK1021547T3 (da) Vaccineformuleringer indeholdende papillomviruskapsomer og fremgangsmåder til anvendelse heraf
HUP0203409A2 (hu) Gamma-interferon-konjugátumok
NO883896L (no) Fremgangsmaate til fremstilling av konjugater av cytokinermed menneskelig immunglobulin.
DE69638120D1 (de) Konditionell replizierende virale Vektoren und ihre Verwendung
NO973663D0 (no) Fremgangsmåte for fremstilling av genomet av rekombinante adenoviruser
NO980203D0 (no) Varianter av proteinet P53 og den terapeutiske anvendelse derav
FR2702152B1 (fr) Virus recombinants et leur utilisation en thérapie génique.
EP1012603A4 (de) Funktionelle fragmente des hiv-1 vpr proteins and eine methode zu seiner anwendung
DK0843731T3 (da) Adenovirusvektorer til genterapi
DE59604375D1 (de) Leberspezifischer adenovirus-expressionsvektor
FI964186A (fi) Ei-liittävät gp350/220-variantit
DK0817859T3 (da) Rekombinante DNA vektorer til Genterapi
ATE269064T1 (de) Impfstoffe gegen den hepatitis b und c virus
WO2001011063A3 (de) Kombinationsvektoren für den gentransfer, verfahren zu ihrer herstellung und ihre verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition